Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humacyte, Inc. - Common Stock (NQ: HUMA )

4.510 -0.140 (-3.01%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humacyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
HUMA Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About the Class Action Against Humacyte, Inc.
From Robbins LLP
Via GlobeNewswire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Spotlight on Humacyte: Analyzing the Surge in Options Activity
Via Benzinga
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
From The Rosen Law Firm PA
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Dow Surges Over 600 Points, Gold Jumps 1.5%
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
Via Benzinga
Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?
Humacyte's Symvess earns FDA approval as a first-in-class bioengineered vascular solution for urgent arterial injury repair in trauma cases. 
Via Benzinga
Exposures Product Safety
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'
U.S. futures declined on Friday, ahead of the 'Triple Witching' hour, which is expected to see $6.6 trillion options expire, for the quarter. 
Via Benzinga
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
From Faruqi & Faruqi LLP
Via GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class Action - HUMA
Via ACCESSWIRE
Humacyte, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – HUMA
Via ACCESSWIRE
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Should Contact Levi & Korsinsky about Pending Class Action - HUMA
Via ACCESSWIRE
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA
Via ACCESSWIRE
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Humacyte Inc
Via ACCESSWIRE
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders
Via ACCESSWIRE
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Via ACCESSWIRE
Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - HUMA
Via ACCESSWIRE
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Via ACCESSWIRE
Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm
Via ACCESSWIRE
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class Action - HUMA
Via ACCESSWIRE
Contact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc.(HUMA)
Via ACCESSWIRE
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – HUMA
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.